

Riverstone Holdings Limited 3Q2020 Corporate Presentation

Disclaimer

This presentation may contain forward looking statements that involve risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in forward looking statements as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other companies, shifts in customer demands, customers and partners, changes in operating expenses, including employee wages, benefits and training, governmental and public policy changes and the continued availability of financing in the amounts and the terms necessary to support future business. You are cautioned not to place undue reliance on these presentation and the information contain therein, which are based on current view of management on future events.

Without prejudice to or derogating from the generality of the foregoing, no representation or assurance is given by Riverstone that this presentation contain all information that an investor may require. To the extent permitted by applicable law, Riverstone or its related persons (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) arising from the reliance or use of the information contain in this presentation.

Investors are advised to make their own independent evaluation from this presentation, consider their own individual investment objectives, financial situation and particular needs and consult their own professional and financial advisers as the legal, business, financial, tax and other aspects as investors may regard as relevant.

Agenda Maeung







Results Overview


Quarterly & YOY Comparison

	3Q2019 (RM '000)	2Q2020 (RM '000)	3Q2020 (RM '000)
Revenue	251,256	347,299	482,341
Gross Profit	51,390	130,596	251,631
Profit Before Tax	41,750	117,237	232,448
Net Profit	35,611	90,925	178,629


	As at 30 September 2020	As at 31 December 2019
Cash & Cash Eq (RM '000)	427,337	130,409

Growing Revenues

Revenue




Gross Profit



Gross Profit


Net Profit




Net Profit

Positive Cash Flow Generation From Operating Activities

Operating CF



Consistent Dividends since IPO



Dividends Declared (RM Sen/Share)~

Adjusted for the 1:1 bonus shares


Dividend Payout Ratio		
FY2019	42.0%	
FY2018	38.6%	
FY2017	40.7%	
FY2016	40.0%	
FY2015	37.8%	
FY2014	36.0%	
FY2013	42.4%	
FY2012	49.3%	
FY2011	48.4%	
FY2010	45.5%	
FY2009	55.6%^	
FY2008	45.2%	
FY2007	45.0%	
FY2006	28.0%	

[^] including a special 1 sen tax-exempt dividend

Agenda Maeung







Group Capacity

Group Capacity

- Y2020:10.5 billion
- Y2021:12.0 billion
- Y2022:13.5 billion
- Y2023:15.0 billion



Eco Medi Glove Sdn Bhd – Plant 2



Protective Technology Co Ltd



Group Capacity



Eco Medi Glove Sdn Bhd – Plant 3

Expansion Focus – Plant 3

Ongoing Expansion Plans

- Acquired two parcels of industrial land in FY2019 (18.4 acres)
- Launched three year
 expansion plan in FY2020
 (Phase 7 9)
- Total annual capacity of the Group projected to reach up to 15.0 billion pieces by end-FY2023

Investment Merits

Plan to increase capacity by 1.5 billion pieces of gloves every year

Resilient balance sheet with net cash position and continued ability to generate positive operating cash flow

Consistent dividend payout since listing

Why we are distinct from our competitors – we have 2 main sources of revenue, namely:

 High tech cleanroom gloves – own brand, direct to end-user; and
 Healthcare gloves –

consistent demand, resilient to changing market conditions



In Summary

- Average selling price of healthcare examination gloves increased 10.0% monthon-month ("mom") from June to October 2020, and 15.0% mom for November and December
- Cleanroom gloves grew >30.0% in the first three quarters of 2020. Increasing trend expected to persist through to 2021
- Overall, average selling prices of both healthcare and cleanroom gloves are expected to continue trending upwards due to strong demand
- Two more double lines to be commissioned in November and December 2020
- Group will add 1.5 billion pieces of gloves in 2021, with the first line of this new Phase 7 ready in April 2021
- All of the new capacity (1.5 billion pieces of gloves) has been booked by customers
- Two further phases from 2022-2023 (Phase 8 9) projected to bring capacity by up to 1.5 billion pieces of gloves per annum to a total of up to 15.0 billion by end-FY2023



Q & A M & M



